The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
|Videos|April 1, 2011
Dr. Twelves Describes Iniparib Clinical Trials
Author(s)Christopher Twelves, MD
Advertisement
Christopher Twelves, MD, Professor of Clinical Cancer Pharmacology and Oncology and Head of the Clinical Cancer Research Group at the University of Leeds in the United Kingdom Describes Iniparib Clinical Trials
Advertisement
Related to this article
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Catch up on insights into the global development of breast cancer treatments in the global spotlight.
First-line pembrolizumab monotherapy met the primary end point of PFS in dMMR advanced/recurrent endometrial cancer.
The FDA approved gedatolisib/fulvestrant, with or without palbociclib, for hormone receptor–positive advanced breast cancer without a PIK3CA mutation.
Read our recap of top phase 1 and 2 breast cancer data highlights that may lead to further clinical research and developments.
Read our recap of the top phase 3 breast cancer data announcements and highlights that may make waves in the future of breast cancer management.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
Dr Falchi on Critical Unmet Needs and Important Next Steps in DLBCL
4
Olverembatinib Plus Blinatumomab Yields High Early-Phase CR/CRi Rates in R/R Ph+ CML and B-ALL
5